Skip to content
Screener

UroGen Pharma URGN Total Cost of Revenue

Discontinued — last reported Q2 '21

Total Cost of Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.73B+10.5%
Pfizer logo
PfizerPFE
$4.09B+8.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$8.05B+5.5%
Merck & Co. logo
Merck & Co.MRK
$4.4B+23.6%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$238K+310%
LQD
Liquidia CorporationLQDA
$1.52M+3.4%

Other financials

Income statement

See full
Revenue$72.5M+199%
Net income-$14.4M+71.3%

Balance sheet

See full
Cash & equivalents$79.1M-14.8%
Total debt$197.5M+55.0%
Total equity-$132.4M-41.8%
Total assets$252.6M+21.0%

Cash flow

See full
Operating cash flow-$33.0M+17.1%
CapEx$60.0K-57.4%
Free cash flow-$33.1M+17.3%

Valuation

See full
Market cap$2.22B+140%
Enterprise value$2.34B+144%
P/S11.8×+2.0×

Profitability

See full
Gross margin89.7%—
Operating margin-329.7%—
Net margin-51.7%-21.0pp
FCF margin-84.3%-22.2pp

Returns & leverage

See full
Return on equity-211.6%—
Debt / equity4.8×—
Current ratio3.8×-0.3×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The source filing: UroGen Pharma’s 10-Q, filed August 4, 2021. Open the filing →

Filed
Aug 4, 2021, 8:09 AM EDT
Fiscal quarter
Q2 FY2021
Calendar quarter
Q2 2021
Accession
0001564590-21-040510

FAQ

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.